Cannabinoids: THC, CBD, and Their Medical Applications
The cannabis plant produces more than 100 distinct chemical compounds called cannabinoids, but two of them — tetrahydrocannabinol (THC) and cannabidiol (CBD) — account for most of the documented clinical activity and virtually all of the regulatory conversation in the United States. Understanding what these compounds do, how they differ, and where the evidence actually supports medical use is the foundation of any serious engagement with medical marijuana programs as they exist today. The distinction matters practically, not just pharmacologically: it determines what a patient can access, under what legal framework, and with what risk profile.
Definition and scope
THC is the primary psychoactive compound in cannabis — the one responsible for the intoxicating effect that made the plant both culturally significant and federally controlled. CBD, by contrast, produces no intoxication and is classified separately enough that the FDA approved a CBD-based pharmaceutical, Epidiolex, for pediatric epilepsy conditions in 2018 (FDA, Epidiolex approval). That single approval cracked open a formal regulatory distinction that had long been papered over.
The federal picture remains split. Cannabis as a whole sits on Schedule I of the Controlled Substances Act (DEA, 21 USC §812), meaning no accepted medical use and high abuse potential — at least by DEA's formal classification. CBD derived from hemp (defined as cannabis with less than 0.3% THC by dry weight under the 2018 Farm Bill) exists in a different legal lane. THC, regardless of origin, stays Schedule I at the federal level, though 38 states had established medical marijuana programs as of 2024, creating the overlapping jurisdictional patchwork that defines the regulatory context for medical marijuana.
Beyond THC and CBD, the cannabinoid family includes CBN (cannabinol), CBG (cannabigerol), and THCV (tetrahydrocannabivarin), among others. These are present in smaller concentrations and carry less clinical evidence, but they contribute to what researchers call the "entourage effect" — the hypothesis, not yet fully validated, that cannabinoids work more effectively in combination than in isolation.
How it works
Both THC and CBD interact with the endocannabinoid system, a signaling network distributed through the brain, immune system, and peripheral tissues. The system has two primary receptor types: CB1, concentrated in the central nervous system, and CB2, found mainly in immune tissue.
THC binds directly to CB1 receptors, which is why it produces psychoactive effects — altered perception, euphoria, and occasionally anxiety or paranoia at high doses. That same CB1 binding also drives analgesic and anti-nausea effects that underpin most of its medical applications. CBD does not bind meaningfully to CB1 or CB2 receptors. Instead, it modulates those receptors indirectly and also interacts with serotonin receptors (5-HT1A) and ion channels involved in pain signaling (TRPV1). This mechanistic difference explains why CBD can reduce seizure frequency or inflammation without producing intoxication.
The pharmacokinetics vary significantly by delivery method. Inhaled THC reaches peak plasma concentration within minutes; oral administration delays onset to 30–90 minutes with variable bioavailability. CBD's oral bioavailability hovers around 6% in most studies, which is why pharmaceutical formulations like Epidiolex use highly purified, precisely dosed preparations rather than consumer products.
Common scenarios
The clinical applications that have accumulated the most evidence break down roughly by compound:
THC-dominant applications:
1. Chronic pain — Particularly neuropathic pain; a 2017 National Academies of Sciences report concluded there was "substantial evidence" supporting cannabis for chronic pain in adults (NASEM, The Health Effects of Cannabis and Cannabinoids, 2017).
2. Chemotherapy-induced nausea — The FDA approved synthetic THC (dronabinol) for this indication in 1985.
3. Appetite stimulation — Particularly in HIV/AIDS-related wasting; dronabinol carries an FDA indication here as well.
4. Muscle spasticity — Evidence is moderate for multiple sclerosis; medical marijuana for multiple sclerosis covers this application in detail.
CBD-dominant applications:
1. Seizure disorders — Dravet syndrome and Lennox-Gastaut syndrome, where Epidiolex has demonstrated efficacy in controlled trials.
2. Anxiety — Preclinical and early clinical evidence is promising, though the evidence base is less robust than for seizure disorders. See medical marijuana for anxiety and PTSD.
3. Inflammation — Under active investigation; not yet supported by large-scale clinical trials.
The FDA-approved cannabis-based medications page maps the full landscape of pharmaceutical-grade products that have cleared the agency's approval process.
Decision boundaries
Not every condition responds the same way to THC, CBD, or a combination, and the ratio matters considerably. High-THC products carry a genuine side effect and safety profile that includes cognitive impairment, cardiovascular effects, and documented risk of cannabis use disorder in approximately 9% of users who try cannabis (National Institute on Drug Abuse, based on data from the 2019 National Survey on Drug Use and Health). Patients with personal or family history of psychosis face elevated risk — a distinction flagged by the safety and risk boundaries framework applicable across state programs.
CBD's safety profile is considerably more favorable, but "well-tolerated" is not the same as inert. At clinical doses, CBD inhibits CYP450 liver enzymes and can alter the metabolism of anticoagulants, antiepileptics, and other medications — a interaction dynamic detailed in medical marijuana drug interactions.
The practical decision framework comes down to three variables: the qualifying condition, the patient's psychiatric and cardiovascular history, and the legal product landscape in the patient's state. A patient managing neuropathic pain in a state with a robust medical program has access to specific strains and formulations that can be calibrated for THC:CBD ratios. A patient in a state that only permits CBD oil exists in a narrower pharmacological lane — but a lane with considerably less regulatory friction. The state-by-state medical marijuana programs page maps exactly where those lines fall.